RICHMOND, Calif., Sept. 12, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data from its ongoing Phase 2 clinical trial (SB-728-902 Cohort 5) to ...

We’ve all sat through our share of boring presentations. It’s mind-numbing to be forced to listen to dry content that’s delivered (or worse, read) at us, rather than discussed with us. Often, all this ...

Single-doses of AB-729 studied to date, 60 mg, 90 mg and 180 mg, resulted in comparable mean HBsAg declines at week 12, followed by a sustained plateau phase. During the multiple-dose portion of the ...

Explore 50+ engaging science debate and presentation topics for school students from Class 4 to 12. Perfect for science fairs, classroom activities, and competitions. Includes high school and middle ...

Addressing safety provides substantial company-wide opportunities and offers benefits such as reduced costs and risks, lower absence and turnover rates, stronger reputation for corporate ...

Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted ...

The data demonstrate functional control of the virus at or below the limit of detection in CCR5 delta-32 heterozygote HIV-infected subjects treated with SB-728-T. The abstract was selected as a ...